Bayer to appeal $2 billion glyphosate-cancer verdict with EPA Roundup assessment excluded from trial

monsanto roundup

Bayer plans to make the EPA’s safety endorsement of a chemical in Roundup central to its case as the company fights claims its weedkiller causes cancer.

In recent months, Bayer has been handed three jury verdicts ordering the company to pay more than $2 billion in damages to plaintiffs who believe exposure to Roundup caused their non-Hodgkin lymphoma ….

…. In April, the EPA released a draft risk assessment stating glyphosate is not a carcinogen …. a conclusion the agency has consistently made as it periodically reviews the herbicide. Attorneys for Bayer tried to introduce that evidence during the third trial …. but were rebuffed by the judge.

Related article:  $10.9 billion Monsanto Roundup settlement does not automatically shield Bayer from 'flood' of new glyphosate-cancer lawsuits

Defense attorneys plan to make that judge’s ruling a key part of their attempt to overturn the third jury verdict during appeal


Read full, original article: Bayer to lean on EPA review of glyphosate in court battles (Behind Paywall)

Outbreak Daily Digest
Biotech Facts & Fallacies
GLP Podcasts
Infographic: Here’s where GM crops are grown around the world today

Infographic: Here’s where GM crops are grown around the world today

Do you know where biotech crops are grown in the world? This updated ISAAA infographics show where biotech crops were ...
News on human & agricultural genetics and biotechnology delivered to your inbox.
glp menu logo outlined

Newsletter Subscription

* indicates required
Email Lists
Send this to a friend